Literature DB >> 2550692

Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.

Y Kawaguchi1.   

Abstract

The concentration of abnormal prothrombin, or the protein induced by vitamin K absence or antagonist II (PIVKA-II) in 102 patients with hepatic disorders was measured by an enzyme immunoassay method. The concentration of PIVKA-II in the plasma was elevated in 11 out of 18 patients with hepatocellular carcinoma and also in a patient with hepatoblastoma. There was no correlation between serum alpha-fetoprotein and plasma PIVKA-II levels. The PIVKA-II level was normal in 11 patients who had metastatic carcinoma or cholangiocellular carcinoma. Moreover, benign diseases of the liver did not cause an elevation in PIVKA-II. PIVKA-II might be an useful marker of hepatocellular carcinoma because, like alpha-fetoprotein, its level changes in close relation to the effects of treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550692     DOI: 10.1007/BF02471405

Source DB:  PubMed          Journal:  Jpn J Surg        ISSN: 0047-1909


  8 in total

1.  A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients.

Authors:  P A Friedman; R D Rosenberg; P V Hauschka; A Fitz-James
Journal:  Biochim Biophys Acta       Date:  1977-09-27

2.  Kinetic aspects of the interaction of blood-clotting enzymes. VI. Localization of the site of blood-coagulation inhibition by the protein induced by vitamin K absence (PIVKA).

Authors:  H C Hemker; A D Muller
Journal:  Thromb Diath Haemorrh       Date:  1968-11-15

3.  Detection of vitamin K deficiency by use of an enzyme-linked immunosorbent assay for circulating abnormal prothrombin.

Authors:  K Motohara; Y Kuroki; H Kan; F Endo; I Matsuda
Journal:  Pediatr Res       Date:  1985-04       Impact factor: 3.756

4.  The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin.

Authors:  G L Nelsestuen; T H Zytkovicz; J B Howard
Journal:  J Biol Chem       Date:  1974-10-10       Impact factor: 5.157

5.  A new method to assay des-gamma-carboxyprothrombin. Results obtained in 75 cases of hepatocellular carcinoma.

Authors:  J P Soulier; D Gozin; J J Lefrere
Journal:  Gastroenterology       Date:  1986-11       Impact factor: 22.682

6.  Vitamin K dependent modifications of glutamic acid residues in prothrombin.

Authors:  J Stenflo; P Fernlund; W Egan; P Roepstorff
Journal:  Proc Natl Acad Sci U S A       Date:  1974-07       Impact factor: 11.205

7.  Acquired vitamin K-dependent carboxylation deficiency in liver disease.

Authors:  R A Blanchard; B C Furie; M Jorgensen; S F Kruger; B Furie
Journal:  N Engl J Med       Date:  1981-07-30       Impact factor: 91.245

8.  Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.

Authors:  H A Liebman; B C Furie; M J Tong; R A Blanchard; K J Lo; S D Lee; M S Coleman; B Furie
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

  8 in total
  1 in total

1.  Role of surgical treatment for recurrent hepatocellular carcinoma after hepatic resection.

Authors:  Y Nakajima; T Ohmura; J Kimura; T Shimamura; K Misawa; M Matsushita; N Sato; Y Une; J Uchino
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.